House Resolution No. by Representative Phelps recognizes gene editing as a significant advancement in the medical and scientific treatment of sickle cell disease, a genetic blood disorder that primarily affects individuals of African ancestry. The resolution highlights the historical context of sickle cell disease, noting its first documentation in 1910 and the challenges faced by patients, including severe pain and complications that can arise from the condition. Prior to 2023, treatment options were limited, primarily focusing on symptom management and bone marrow transplants, which are difficult to obtain due to genetic compatibility issues.

The resolution celebrates the recent approval by the FDA of two groundbreaking gene therapies, Casgevy and Lyfgenia, which represent the first cell-based treatments for sickle cell disease in patients aged twelve and older. Notably, Casgevy utilizes CRISPR/Cas9 gene editing technology to modify a patient's own bone marrow cells to produce healthy blood cells. The resolution acknowledges Children's Hospital New Orleans as one of the first hospitals authorized to administer Casgevy, and it calls for the distribution of the resolution to various organizations and individuals involved in sickle cell disease advocacy and treatment.